Articles: stroke.
-
Despite the approval of the use of tissue plasminogen activator for the treatment of acute stroke, less than 10% of all patients with stroke are able to reach a medical facility in time to receive the treatment. This article reviews the current concepts of stroke management and emphasizes the importance of public awareness for the signs and symptoms of stroke and the need for immediate attention when a stroke is suspected.
-
The heart surgery forum · Jan 1999
ReviewEndarterectomy for preventing stroke in symptomatic and asymptomatic carotid stenosis. Review of clinical trials and recommendations for surgical therapy.
Multicenter, randomized trials have demonstrated advantages for surgery over medical therapy in both symptomatic and asymptomatic carotid stenosis of greater than 70%. Controversial interpretations of these trials are debated between medical and surgical camps. The goal of this review is to summarize the current state of knowledge in carotid stenosis and the role of surgery and several advances in operative management. ⋯ Randomized trials support the safety and efficacy of carotid endarterectomy for stenosis greater than 70% (with or without symptoms). Advantages of surgery over medical therapy were found in less than three years and there is ample evidence to suggest that the differences between these groups would have been even more pronounced had longer follow-up been obtained. Thus for patients who face many years of risk after diagnosis of a carotid lesion, early surgery is the most important and effective intervention for preventing stroke. The results of these trials raised initial concern over increasing health care expenditures from rising surgical case volumes. However, studies of cost effectiveness confirmed that surgery saves health care dollars when compared to the long term care of stroke victims.
-
Ann. N. Y. Acad. Sci. · Jan 1999
Randomized Controlled Trial Clinical TrialA double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of CP-101,606 in patients with a mild or moderate traumatic brain injury.
CP-101,606 is a postsynaptic antagonist of the glutamate-mediated NR2B subunit of the N-methyl-D-aspartate (NMDA) receptor. When administered intravenously (i.v.) at the time of injury, CP-101,606 is neuroprotective in animal models of traumatic brain injury (TBI) and ischemia. Minimal adverse effects have been observed in normal human volunteers given i.v. doses of up to 3 mg/kg/hr for 72 hours. ⋯ A Neurobehavioral Rating Scale, used to detect personality changes and behavioral disturbances, indicated that all subjects showed an improvement from their postinjury, predosing baseline but did not significantly differ from each other with respect to type of head injury and/or treatment with drug or placebo. Modified Kurtzke Scoring also showed a similar pattern of improvement irrespective of type of head injury or drug/placebo treatment. This study suggests that CP-101,606, infused for up to 72 hours has no psychotropic effects and is well-tolerated in patients who have sustained a mild or moderate TBI or hemorrhagic stroke.